Literature DB >> 17351647

Combined inhaled steroids and bronchodilatators in obstructive airway disease after allogeneic stem cell transplantation.

A Bergeron1, A Belle, S Chevret, P Ribaud, A Devergie, H Esperou, L Ades, E Gluckman, G Socié, A Tazi.   

Abstract

Bronchiolitis obliterans (BO) is a potentially life-threatening complication following allogeneic stem cell transplantation (SCT) and usually carries a poor prognosis. Immunosuppressive medications are the main treatment, but are rarely effective, especially when the disease is severe. Thus, both early detection and alternative therapeutic approaches of post SCT BO are needed. We report our experience with Budesonide/Formoterol, an inhaled steroid and long-acting bronchodilatator combination, in a group of patients with mild to moderately severe BO after SCT whose systemic immunosuppressive treatment had not been modified. Thirteen patients were treated. The diagnosis of BO was based on the presence of respiratory symptoms and air-trapping on expiratory lung high-resolution computed tomography in all patients, associated with irreversible airflow obstruction in seven cases. The median follow-up was 12.8 months (range: 5-29 months). All patients improved clinically, and both forced expiratory volume in 1 (FEV(1)) and mean expiratory flow values increased significantly during follow-up (534+/-268 ml in absolute values and 36+/-27% compared to pretreatment values for FEV(1); P<0.02). These encouraging results provide new insights in the therapeutic approach of BO after SCT and require confirmation in a larger group of patients with a longer follow-up.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17351647     DOI: 10.1038/sj.bmt.1705637

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  17 in total

Review 1.  Regulatory T cells in lung transplantation--an emerging concept.

Authors:  David C Neujahr; Christian P Larsen
Journal:  Semin Immunopathol       Date:  2011-03-20       Impact factor: 9.623

2.  A call to arms: a critical need for interventions to limit pulmonary toxicity in the stem cell transplantation patient population.

Authors:  Sabarinath Venniyil Radhakrishnan; Gerhard C Hildebrandt
Journal:  Curr Hematol Malig Rep       Date:  2015-03       Impact factor: 3.952

Review 3.  How I treat bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation.

Authors:  Kirsten M Williams
Journal:  Blood       Date:  2016-11-16       Impact factor: 22.113

4.  Fluticasone, Azithromycin, and Montelukast Treatment for New-Onset Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation.

Authors:  Kirsten M Williams; Guang-Shing Cheng; Iskra Pusic; Madan Jagasia; Linda Burns; Vincent T Ho; Joseph Pidala; Jeanne Palmer; Laura Johnston; Sebastian Mayer; Jason W Chien; David A Jacobsohn; Steven Z Pavletic; Paul J Martin; Barry E Storer; Yoshihiro Inamoto; Xiaoyu Chai; Mary E D Flowers; Stephanie J Lee
Journal:  Biol Blood Marrow Transplant       Date:  2015-10-22       Impact factor: 5.742

5.  Soluble tumor necrosis factor receptor: enbrel (etanercept) for subacute pulmonary dysfunction following allogeneic stem cell transplantation.

Authors:  Gregory A Yanik; Shin Mineishi; John E Levine; Carrie L Kitko; Eric S White; Mark T Vander Lugt; Andrew C Harris; Thomas Braun; Kenneth R Cooke
Journal:  Biol Blood Marrow Transplant       Date:  2011-12-10       Impact factor: 5.742

6.  The efficacy of prophylactic azithromycin on bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation.

Authors:  Kyung-Wook Jo; Shinkyo Yoon; Jin Woo Song; Tae Sun Shim; Sei Won Lee; Jae Seung Lee; Dae-Young Kim; Je-Hwan Lee; Jung-Hee Lee; Yunsuk Choi; Kyoo-Hyung Lee
Journal:  Int J Hematol       Date:  2015-06-30       Impact factor: 2.490

7.  National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: V. The 2014 Ancillary Therapy and Supportive Care Working Group Report.

Authors:  Paul A Carpenter; Carrie L Kitko; Sharon Elad; Mary E D Flowers; Juan C Gea-Banacloche; Jörg P Halter; Flora Hoodin; Laura Johnston; Anita Lawitschka; George B McDonald; Anthony W Opipari; Bipin N Savani; Kirk R Schultz; Sean R Smith; Karen L Syrjala; Nathaniel Treister; Georgia B Vogelsang; Kirsten M Williams; Steven Z Pavletic; Paul J Martin; Stephanie J Lee; Daniel R Couriel
Journal:  Biol Blood Marrow Transplant       Date:  2015-03-31       Impact factor: 5.742

8.  Inhaled Bronchodilators and Corticosteroids in the Management of Bronchiolitis Obliterans due to Allogenic Hematopoietic Stem Cell Transplantation.

Authors:  Vasiliki Epameinondas Georgakopoulou; Aikaterini Gkoufa; Nikolaos Garmpis; Anna Garmpi; Christos Damaskos
Journal:  Oman Med J       Date:  2022-05-31

Review 9.  Airway disease in hematologic malignancies.

Authors:  Ricardo J José; Burton F Dickey; Ajay Sheshadri
Journal:  Expert Rev Respir Med       Date:  2022-02-21       Impact factor: 4.300

Review 10.  Azithromycin for the Treatment of Obliterative Bronchiolitis after Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis.

Authors:  Hemang Yadav; Steve G Peters; Karina A Keogh; William J Hogan; Patricia J Erwin; Colin P West; Cassie C Kennedy
Journal:  Biol Blood Marrow Transplant       Date:  2016-08-26       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.